PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity

By sjmartinez • November 27, 2024

Varuzhanyan G, Chen CC, Freeland J, He T, Tran W, Song K, Wang L, Cheng D, Xu S, Dibernardo GA, Esedebe FN, Bhatia V, Han M, Abt ER, Park JW, Memarzadeh S, Shackelford DB, Lee JK, Graeber TG, Shirihai OS, Witte ON. PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2416882121. doi: 10.1073/pnas.2416882121. Epub 2024 Nov 26. PMID: 39589879.

Tags: ASCL1, Endocrinology, Hematology/Oncology, Lung cancer, Oxidative phosphorylation, PGC-1a, prostate cancer, Publications, Pulmonary, Critical Care & Sleep Medicine

Stabilizing and strengthening the U.S. physician-scientist faculty workforce in academic medicine: a proposed institutional framework

Williams CS, Allen M, Cooper Byas P, Hawley JB, Muglia LJ, Abel ED, Bastarache JA, Calfee CS, Carethers JM, Cornfield DN, Eickelberg O, Gallagher EJ,[...]

The effectiveness of care coordination on medication adherence among high-need, high-cost commercially insured beneficiaries: A randomized controlled trial

Saju R, Harwood JM, Tseng CH, Moin T, Mangione C, Duru OK, Takada S, Onufrak S. The effectiveness of care coordination on medication adherence among[...]

Systems Genetics Reveals ITIH5 as a Key Mediator of Adipocyte-Endothelial Crosstalk

Zhou M, Velez LM, Kwan D, Moses L, Johnson CD, Nguyen CM, Mott L, Gamie F, Fouladi M, Bae H, Verlande A, Arneson D, Petrus[...]